Skip to main content
. 2022 May 5;49(6):86. doi: 10.3892/ijmm.2022.5142

Figure 1.

Figure 1

Intranasal administration of IL-27 following sensitization with OVA cannot alleviate airway inflammation and AHR in an acute model of experimental allergic asthma. (A and B) Protocol of OVA-induced allergic asthma and administration of IL-27. (C) AHR was invasively measured by lung resistance and compliance in response to increasing concentrations of methacholine. Treatment with IL-27 did not improve lung resistance and lung compliance. (D) Total cell number and the differential cell counts in the BALF samples. The total cell number and the differential cell counts exhibited no significant difference between the OVA + IL-27 group and OVA group. The data are expressed as the mean ± SEM of three independent experiments, with 8 animals per group. *P<0.05, **P<0.01, ***P<0.001. IL-27, interleukin 27; OVA, ovalbumin; AHR, airway hyperresponsiveness; BALF, bronchoalveolar lavage fluid; i.n., intranasal.